1. Home
  2. VERU vs PLRX Comparison

VERU vs PLRX Comparison

Compare VERU & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERU
  • PLRX
  • Stock Information
  • Founded
  • VERU 1971
  • PLRX 2015
  • Country
  • VERU United States
  • PLRX United States
  • Employees
  • VERU N/A
  • PLRX N/A
  • Industry
  • VERU Biotechnology: Pharmaceutical Preparations
  • PLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • VERU Health Care
  • PLRX Health Care
  • Exchange
  • VERU Nasdaq
  • PLRX Nasdaq
  • Market Cap
  • VERU 85.5M
  • PLRX 97.6M
  • IPO Year
  • VERU 1990
  • PLRX 2020
  • Fundamental
  • Price
  • VERU $0.49
  • PLRX $1.52
  • Analyst Decision
  • VERU Strong Buy
  • PLRX Hold
  • Analyst Count
  • VERU 2
  • PLRX 10
  • Target Price
  • VERU $4.00
  • PLRX $9.79
  • AVG Volume (30 Days)
  • VERU 1.4M
  • PLRX 1.2M
  • Earning Date
  • VERU 08-07-2025
  • PLRX 08-06-2025
  • Dividend Yield
  • VERU N/A
  • PLRX N/A
  • EPS Growth
  • VERU N/A
  • PLRX N/A
  • EPS
  • VERU N/A
  • PLRX N/A
  • Revenue
  • VERU $16,886,419.00
  • PLRX N/A
  • Revenue This Year
  • VERU N/A
  • PLRX N/A
  • Revenue Next Year
  • VERU N/A
  • PLRX N/A
  • P/E Ratio
  • VERU N/A
  • PLRX N/A
  • Revenue Growth
  • VERU 134.43
  • PLRX N/A
  • 52 Week Low
  • VERU $0.45
  • PLRX $1.10
  • 52 Week High
  • VERU $1.42
  • PLRX $16.10
  • Technical
  • Relative Strength Index (RSI)
  • VERU 35.42
  • PLRX 56.00
  • Support Level
  • VERU $0.49
  • PLRX $1.55
  • Resistance Level
  • VERU $0.61
  • PLRX $1.61
  • Average True Range (ATR)
  • VERU 0.04
  • PLRX 0.10
  • MACD
  • VERU -0.01
  • PLRX 0.01
  • Stochastic Oscillator
  • VERU 2.27
  • PLRX 62.50

About VERU Veru Inc.

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Share on Social Networks: